Precigen, Inc.
PGENNext catalyst
PRGN-2009 plus Pembrolizumab
Cervical Cancer
Get an email about PGEN's next catalysts
Track Precigen (PGEN) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 2 past
PRGN-2009 plus Pembrolizumab Phase 2 Est. Readout
Primary completion for PRGN-2009 plus Pembrolizumab trial (NCT06157151) in Cervical Cancer
SourceMarket Overview
Stock performance and key metrics
Precigen, Inc. (formerly Intrexon Corporation, NASDAQ: PGEN) is an American biotechnology company. Its president and CEO is Helen Sabzevari. Intrexon was founded in 1998, and is headquartered in Germantown, Maryland. With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells.
WebsitePRGN-2009 plus Pembrolizumab
Cervical Cancer
PRGN-2012 - Phase I; Dose Level 1
Recurrent Respiratory Papillomatosis
AG019 - Low Dose
Diabetes type1
PRGN-2012 - Phase I; Dose Level 2
Recurrent Respiratory Papillomatosis
PRGN-2012 - Phase II; Dose Level 2
Recurrent Respiratory Papillomatosis
AG019 - High Dose
Diabetes type1
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PRGN-2009 plus Pembrolizumab | Phase 2 | Cervical Cancer | - | - |
PRGN-2012 - Phase I; Dose Level 1 | Phase 2 | Recurrent Respiratory Papillomatosis | - | - |
AG019 - Low Dose | Phase 2 | Diabetes type1 | - | - |
PRGN-2012 - Phase I; Dose Level 2 | Phase 2 | Recurrent Respiratory Papillomatosis | - | - |
PRGN-2012 - Phase II; Dose Level 2 | Phase 2 | Recurrent Respiratory Papillomatosis | - | - |
AG019 - High Dose | Phase 2 | Diabetes type1 | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Precigen, Inc.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in Precigen, Inc.'s (PGEN) pipeline across Phase 2. Its lead program is PRGN-2009 plus Pembrolizumab (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Precigen, Inc.'s next FDA catalyst?→
Precigen, Inc.'s (PGEN) next tracked catalyst is a Phase 2 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PGEN biotech catalysts?→
Add PGEN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Precigen, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.